{"slug":"ara-290","verification":{"valid":false,"broken_at":0,"reason":"prev mismatch"},"count":13,"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/23168581/","title":"Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study","quote":"The ARA 290 group showed significant (p < 0.05) improvement at wk 4 in SFNSL score compared with placebo","claim_ids":["c4"]},{"id":"s2","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT02039687","title":"Phase 2 Dose Ranging Study of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms in Sarcoidosis","quote":"activate repair mechanisms and accelerate healing, including the nerve damage that can be associated with sarcoidosis","claim_ids":["c5"]},{"id":"s3","type":"pubmed","url":"https://research.manchester.ac.uk/en/publications/cibinetide-improves-corneal-nerve-fiber-abundance-in-patients-wit/","title":"Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain","quote":"The placebo-corrected mean change from baseline CNFA at day 28 was 697 (159, 1236; P = 0.012)","claim_ids":["c5"]},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/25387363/","title":"ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes","quote":"Subjects receiving ARA 290 exhibited an improvement in hemoglobin A1c and lipid profiles throughout the 56 d observation period.","claim_ids":["c6"]},{"id":"s5","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3928087/","title":"ARA 290 produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response","quote":"ARA290 dose-dependently reduced allodynia coupled to suppression of the spinal microglia response","claim_ids":["c7"]},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/26683514/","title":"A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets","quote":"Secretion of pro-inflammatory cytokines (IL-6, IL-12, and TNF-alpha) from macrophages was significantly inhibited by ARA 290.","claim_ids":["c8"]},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20660739/","title":"Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin","quote":"HBSP protects cardiomyocytes from apoptosis and leads to a favorable outcome in failing hearts","claim_ids":["c9"]},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/15456912/","title":"Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor","quote":"EpoR and betacR comprise a tissue-protective heteroreceptor.","claim_ids":["c1","c3"]},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18676614/","title":"Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin","quote":"the tissue-protective activities of EPO are mimicked by small, nonerythropoietic peptides that simulate a portion of EPO's three-dimensional structure.","claim_ids":["c1","c3"]},{"id":"s11","type":"news","url":"https://superpower.com/guides/ara-290","title":"ARA-290 (Cibinetide): An EPO-Derived 11-Amino-Acid Peptide Targeting the Innate Repair Receptor","quote":"not stimulate erythropoiesis or raise red blood cell counts","claim_ids":["c2"]},{"id":"s12","type":"news","url":"https://sarcoidosisnews.com/news/cibinetide-seems-to-regenerate-nerve-fibers-improve-pain-in-sarcoidosis-patients/","title":"Cibinetide Seems to Regenerate Nerve Fibers, Improve Pain in Sarcoidosis Patients","quote":"cibinetide (ARA 290) was shown to promote significant corneal nerve and improve pain and functional capacity in a clinical trial with sarcoidosis patients.","claim_ids":["c5"]},{"id":"s13","type":"news","url":"https://diaryofrecovery.com/ara/","title":"ARA 290 for Nerve Pain & Regeneration (first-person account)","quote":"I went from 3 weeks of being unable to put on pants or get in the car without stabbing pain, to zero pain.","claim_ids":["c10"]},{"id":"s14","type":"news","url":"https://www.prnewswire.com/news-releases/araim-pharmaceuticals-receives-orphan-drug-designation-from-the-us-fda-for-ara-290-for-the-treatment-of-sarcoidosis-300293773.html","title":"Araim Pharmaceuticals Receives FDA Orphan Drug Designation for ARA 290 (sarcoidosis)","quote":"Orphan Drug Designation from the US FDA for ARA 290 for the Treatment of Sarcoidosis","claim_ids":[]}]}